Glenmark inks agreement with Astrazeneca
As per this agreement, Astrazeneca remains the holder of the registration for Pulmicort Respules® and will ...
Read moreAs per this agreement, Astrazeneca remains the holder of the registration for Pulmicort Respules® and will ...
Read moreUpdated results from the positive PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful ...
Read moreAstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients ...
Read moreAstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S ), formerly AZD1222, has been granted a special approval for emergency use in Japan for ...
Read moreNAVIGATOR Data Published in New England Journal of Medicine, and Latest Data from Tezepelumab Clinical Program ...
Read moreU.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney ...
Read moreNirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season. Nirsevimab met its Phase ...
Read moreThe benefits of vaccination continue to outweigh any risks but the MHRA advises careful consideration be given to ...
Read moreAstraZeneca issued statement that "there are no exports currently planned other than to COVAX countries. There ...
Read more76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation 85% ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.